Loading...

ACADIA Pharmaceuticals

DB:DR6
Snowflake Description

Flawless balance sheet with high growth potential.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
DR6
DB
$3B
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The last earnings update was 57 days ago. More info.


Add to Portfolio Compare Print
DR6 Share Price and Events
7 Day Returns
4.3%
DB:DR6
0.4%
DE Biotechs
0.8%
DE Market
1 Year Returns
69.3%
DB:DR6
-5.6%
DE Biotechs
-4.5%
DE Market
DR6 Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
ACADIA Pharmaceuticals (DR6) 4.3% -8.4% 10.5% 69.3% -26.3% 52.4%
DE Biotechs 0.4% 7.3% -6.5% -5.6% 51.9% 10.5%
DE Market 0.8% 6.9% 8.1% -4.5% 10.4% 13.9%
1 Year Return vs Industry and Market
  • DR6 outperformed the Biotechs industry which returned -5.6% over the past year.
  • DR6 outperformed the Market in Germany which returned -4.5% over the past year.
Price Volatility
DR6
Industry
5yr Volatility vs Market
Related Companies

Value

 Is ACADIA Pharmaceuticals undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of ACADIA Pharmaceuticals to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for ACADIA Pharmaceuticals.

DB:DR6 Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 12 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 8%
Perpetual Growth Rate 10-Year DE Government Bond Rate 0.2%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for DB:DR6
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year DE Govt Bond Rate 0.2%
Equity Risk Premium S&P Global 6%
Biotechs Unlevered Beta Simply Wall St/ S&P Global 1.45
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.453 (1 + (1- 21%) (0%))
1.303
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.3
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 0.23% + (1.303 * 5.96%)
8%

Discounted Cash Flow Calculation for DB:DR6 using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for ACADIA Pharmaceuticals is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

DB:DR6 DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (USD, Millions) Source Present Value
Discounted (@ 8%)
2019 -191.75 Analyst x4 -177.55
2020 -103.90 Analyst x4 -89.08
2021 164.90 Analyst x3 130.92
2022 358.27 Analyst x3 263.37
2023 470.35 Analyst x2 320.16
2024 559.80 Est @ 19.02% 352.84
2025 634.71 Est @ 13.38% 370.43
2026 694.60 Est @ 9.44% 375.37
2027 740.95 Est @ 6.67% 370.77
2028 776.06 Est @ 4.74% 359.58
Present value of next 10 years cash flows $2,276.80
DB:DR6 DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2028 × (1 + g) ÷ (Discount Rate – g)
= $776.06 × (1 + 0.23%) ÷ (8% – 0.23%)
$10,012.67
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= $10,012.67 ÷ (1 + 8%)10
$4,639.31
DB:DR6 Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= $2,276.80 + $4,639.31
$6,916.12
Equity Value per Share
(USD)
= Total value / Shares Outstanding
= $6,916.12 / 143.88
$48.07
DB:DR6 Discount to Share Price
Calculation Result
Non-primary Listing Adjustment Factor 1 share in DB:DR6 represents 0.89563x of NasdaqGS:ACAD
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
0.89563x
Value per Share
(Listing Adjusted, EUR)
= Value per Share (USD) x Listing Adjustment Factor
= $ 48.07 x 0.89563
€43.05
Value per share (EUR) From above. €43.05
Current discount Discount to share price of €21.54
= -1 x (€21.54 - €43.05) / €43.05
50%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price ACADIA Pharmaceuticals is available for.
Intrinsic value
50%
Share price is €21.54 vs Future cash flow value of €43.05
Current Discount Checks
For ACADIA Pharmaceuticals to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • ACADIA Pharmaceuticals's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • ACADIA Pharmaceuticals's share price is below the future cash flow value, and at a substantial discount (> 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for ACADIA Pharmaceuticals's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are ACADIA Pharmaceuticals's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:DR6 PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in USD $-1.94
NasdaqGS:ACAD Share Price ** NasdaqGS (2019-04-25) in USD $24.05
Europe Biotechs Industry PE Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 22.58x
Germany Market PE Ratio Median Figure of 424 Publicly-Listed Companies 20.1x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of ACADIA Pharmaceuticals.

DB:DR6 PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGS:ACAD Share Price ÷ EPS (both in USD)

= 24.05 ÷ -1.94

-12.42x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • ACADIA Pharmaceuticals is loss making, we can't compare its value to the Europe Biotechs industry average.
  • ACADIA Pharmaceuticals is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does ACADIA Pharmaceuticals's expected growth come at a high price?
Raw Data
DB:DR6 PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -12.42x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 12 Analysts
53%per year
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.33x
Germany Market PEG Ratio Median Figure of 268 Publicly-Listed Companies 1.57x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for ACADIA Pharmaceuticals, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on ACADIA Pharmaceuticals's assets?
Raw Data
DB:DR6 PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in USD $3.33
NasdaqGS:ACAD Share Price * NasdaqGS (2019-04-25) in USD $24.05
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.83x
Germany Market PB Ratio Median Figure of 574 Publicly-Listed Companies 1.87x
DB:DR6 PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGS:ACAD Share Price ÷ Book Value per Share (both in USD)

= 24.05 ÷ 3.33

7.22x

* Primary Listing of ACADIA Pharmaceuticals.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • ACADIA Pharmaceuticals is overvalued based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess ACADIA Pharmaceuticals's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. ACADIA Pharmaceuticals has a total score of 2/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is ACADIA Pharmaceuticals expected to perform in the next 1 to 3 years based on estimates from 12 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
53%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is ACADIA Pharmaceuticals expected to grow at an attractive rate?
  • ACADIA Pharmaceuticals's earnings growth is expected to exceed the low risk savings rate of 0.2%.
Growth vs Market Checks
  • ACADIA Pharmaceuticals's earnings growth is expected to exceed the Germany market average.
  • ACADIA Pharmaceuticals's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:DR6 Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:DR6 Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 12 Analysts 53%
DB:DR6 Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 12 Analysts 30%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.5%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26.1%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.8%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:DR6 Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 12 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:DR6 Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 1,173 580 550 3
2022-12-31 954 341 381 4
2021-12-31 797 141 141 7
2020-12-31 423 -91 -166 11
2019-12-31 292 -185 -271 12
DB:DR6 Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-12-31 224 -167 -245
2018-09-30 208 -158 -249
2018-06-30 185 -175 -252
2018-03-31 158 -193 -256
2017-12-31 125 -218 -289
2017-09-30 93 -251 -299
2017-06-30 63 -242 -306
2017-03-31 33 -240 -309
2016-12-31 17 -208 -271
2016-09-30 5 -182 -238
2016-06-30 0 -165 -206
2016-03-31 0 -138 -174

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • ACADIA Pharmaceuticals's earnings are expected to grow significantly at over 20% yearly.
  • ACADIA Pharmaceuticals's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:DR6 Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 12 Analyst Estimates (S&P Global) See Below

All data from ACADIA Pharmaceuticals Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:DR6 Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 3.37 3.44 3.30 2.00
2022-12-31 2.78 3.48 2.07 2.00
2021-12-31 1.24 3.38 -0.42 6.00
2020-12-31 -1.09 -0.24 -1.99 10.00
2019-12-31 -1.89 -1.69 -2.10 11.00
DB:DR6 Past Financials Data
Date (Data in USD Millions) EPS *
2018-12-31 -1.94
2018-09-30 -1.99
2018-06-30 -2.03
2018-03-31 -2.07
2017-12-31 -2.36
2017-09-30 -2.46
2017-06-30 -2.53
2017-03-31 -2.61
2016-12-31 -2.34
2016-09-30 -2.15
2016-06-30 -1.93
2016-03-31 -1.68

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if ACADIA Pharmaceuticals will efficiently use shareholders’ funds in the future (Return on Equity greater than 20%) as it is not expected to be profitable.
X
Future performance checks
We assess ACADIA Pharmaceuticals's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
ACADIA Pharmaceuticals has a total score of 5/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has ACADIA Pharmaceuticals performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare ACADIA Pharmaceuticals's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • ACADIA Pharmaceuticals does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare ACADIA Pharmaceuticals's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare ACADIA Pharmaceuticals's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
ACADIA Pharmaceuticals's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from ACADIA Pharmaceuticals Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:DR6 Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 223.81 -245.19 265.76
2018-09-30 207.80 -248.57 258.18
2018-06-30 185.07 -251.68 258.68
2018-03-31 158.48 -255.86 250.33
2017-12-31 124.90 -289.40 255.06
2017-09-30 93.30 -299.23 246.04
2017-06-30 62.99 -305.59 234.98
2017-03-31 32.61 -309.47 224.63
2016-12-31 17.33 -271.39 186.46
2016-09-30 5.39 -238.48 151.41
2016-06-30 0.16 -205.77 121.18
2016-03-31 0.06 -173.83 91.53
2015-12-31 0.06 -164.44 78.70
2015-09-30 0.09 -147.03 66.51
2015-06-30 0.07 -132.91 54.26
2015-03-31 0.09 -115.02 41.09
2014-12-31 0.12 -92.48 32.75
2014-09-30 0.11 -76.16 26.60
2014-06-30 0.34 -62.07 22.35
2014-03-31 0.76 -49.65 16.89
2013-12-31 1.15 -37.95 12.72
2013-09-30 1.49 -32.71 10.74
2013-06-30 4.73 -24.42 8.43
2013-03-31 4.87 -20.75 7.49
2012-12-31 4.91 -20.85 7.00
2012-09-30 5.12 -19.34 6.18
2012-06-30 2.22 -22.01 6.21

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if ACADIA Pharmaceuticals has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if ACADIA Pharmaceuticals has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if ACADIA Pharmaceuticals improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess ACADIA Pharmaceuticals's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
ACADIA Pharmaceuticals has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is ACADIA Pharmaceuticals's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up ACADIA Pharmaceuticals's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • ACADIA Pharmaceuticals is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • ACADIA Pharmaceuticals's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of ACADIA Pharmaceuticals's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • ACADIA Pharmaceuticals has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from ACADIA Pharmaceuticals Company Filings, last reported 3 months ago.

DB:DR6 Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 479.08 0.00 473.52
2018-09-30 223.44 0.00 214.14
2018-06-30 264.72 0.00 256.86
2018-03-31 304.17 0.00 298.06
2017-12-31 335.29 0.00 341.34
2017-09-30 377.33 0.00 366.63
2017-06-30 415.14 0.00 417.32
2017-03-31 457.52 0.00 469.48
2016-12-31 518.41 0.00 529.04
2016-09-30 578.06 0.00 588.86
2016-06-30 408.82 0.00 412.56
2016-03-31 445.25 0.00 457.24
2015-12-31 199.76 0.00 215.13
2015-09-30 227.35 0.00 240.69
2015-06-30 255.82 0.00 270.78
2015-03-31 285.09 0.00 297.89
2014-12-31 309.49 0.00 322.49
2014-09-30 330.49 0.00 337.80
2014-06-30 350.11 0.00 354.45
2014-03-31 365.46 0.00 369.29
2013-12-31 182.13 0.00 185.79
2013-09-30 180.75 0.00 196.18
2013-06-30 181.48 0.00 205.45
2013-03-31 79.66 0.00 101.46
2012-12-31 84.98 0.00 107.97
2012-09-30 17.66 0.00 23.06
2012-06-30 12.71 0.01 21.35
  • ACADIA Pharmaceuticals has no debt.
  • ACADIA Pharmaceuticals had no debt 5 years ago.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • ACADIA Pharmaceuticals has sufficient cash runway for 2.8 years based on current free cash flow.
  • ACADIA Pharmaceuticals has sufficient cash runway for 2.7 years if free cash flow continues to grow at historical rates of 4.5% each year.
X
Financial health checks
We assess ACADIA Pharmaceuticals's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. ACADIA Pharmaceuticals has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is ACADIA Pharmaceuticals's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from ACADIA Pharmaceuticals dividends. Estimated to be 0% next year.
If you bought €2,000 of ACADIA Pharmaceuticals shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate ACADIA Pharmaceuticals's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate ACADIA Pharmaceuticals's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:DR6 Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 12 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 326 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:DR6 Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31 0.00 1.00
2020-12-31 0.00 2.00
2019-12-31 0.00 2.00

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as ACADIA Pharmaceuticals has not reported any payouts.
  • Unable to verify if ACADIA Pharmaceuticals's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of ACADIA Pharmaceuticals's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as ACADIA Pharmaceuticals has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of ACADIA Pharmaceuticals's dividends in 3 years as they are not expected to pay a notable one for Germany.
X
Income/ dividend checks
We assess ACADIA Pharmaceuticals's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can ACADIA Pharmaceuticals afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. ACADIA Pharmaceuticals has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of ACADIA Pharmaceuticals's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Steve Davis
COMPENSATION $15,158,146
AGE 57
TENURE AS CEO 3.6 years
CEO Bio

Mr. Stephen R. Davis, also known as Steve, J.D., has been the Chief Executive Officer of ACADIA Pharmaceuticals, Inc. since September 1, 2015 and served as its Chief Financial Officer from July 15, 2014 to September 6, 2015. Mr. Davis served as President of ACADIA Pharmaceuticals, Inc. since September 1, 2015 until November 19, 2018. He served as the Chief Business Officer and Executive Vice President of ACADIA Pharmaceuticals, Inc. from July 15, 2014 to September 1, 2015 and as its Interim Chief Executive Officer from March 2015 to August 2015. Mr. Davis served as the Chief Operating Officer and Executive Vice President of Heron Therapeutics, Inc. from May 2, 2013 to July 2, 2014. Mr. Davis has over 20 years of executive-level experience in the pharmaceutical industry. He served as Chief Financial Officer and Chief Accounting Officer of Heron Therapeutics, Inc. since October 29, 2013. He served as the Chief Operating Officer and Executive Vice President at Ardea Biosciences, Inc. from April 6, 2010 to 2013. He served at Neurogen Corporation as Chief Executive Officer since February 2008, President since September 2007, Chief Operating Officer since April 2005, Principal Financial Officer from 1994 to April 2008, Chief Business Officer from January 2001 to April 2008, Executive Vice President since September 2001, Secretary until February 21, 2007 and Director since September 2001. He joined Neurogen Corp., in 1994 as Vice President of Finance and was responsible for its business operations including the business development, finance and legal functions. From 1990 to June 1994, he was corporate and securities attorney at Milbank, Tweed, Hadley & McCloy LLP. He practiced as a Certified Public Accountant with Arthur Andersen & Co. and as a corporate and securities attorney with a Wall Street law firm. He has been a Director at Bellicum Pharmaceuticals, Inc. since July 2015. He has been a Director of Furiex Pharmaceuticals, Inc since May 24, 2013 and ACADIA Pharmaceuticals, Inc. since September 2015. He served as a Director of Synageva BioPharma Corp. from November 2011 to June 22, 2015. He served as a Director of Trimeris Inc. since June 2007. He served as a Director of Heron Therapeutics, Inc. from February 2010 to February 23, 2011 and again since June 2012. He served as a Director of Neurogen from September 2001 to December 2009. Mr. Davis received his BS in Accounting from Southern Nazarene University and a JD degree from Vanderbilt University.

CEO Compensation
  • Steve's compensation has increased whilst company is loss making.
  • Steve's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the ACADIA Pharmaceuticals management team in years:

0.8
Average Tenure
56.5
Average Age
  • The average tenure for the ACADIA Pharmaceuticals management team is less than 2 years, this suggests a new team.
Management Team

Steve Davis

TITLE
CEO & Director
COMPENSATION
$15M
AGE
57
TENURE
3.6 yrs

Serge Stankovic

TITLE
President
COMPENSATION
$7M
AGE
61
TENURE
0.4 yrs

Michael Yang

TITLE
Executive VP & Chief Commercial Officer
COMPENSATION
$12M
AGE
56
TENURE
2.1 yrs

Elena Ridloff

TITLE
Executive VP & CFO
AGE
38
TENURE
0.5 yrs

Eric Miller

TITLE
Controller & Principal Accounting Officer
AGE
39
TENURE
0.4 yrs

Bob Mischler

TITLE
Senior Vice President of Strategy & Technology Operations

Eliseo Salinas

TITLE
Senior VP
AGE
62
TENURE
0.6 yrs

Ryan Brown

TITLE
Chief Compliance Officer & VP
TENURE
3.7 yrs

Austin Kim

TITLE
Executive VP
TENURE
0.8 yrs

Bill Keller

TITLE
Vice President of Marketing
TENURE
3.6 yrs
Board of Directors Tenure

Average tenure and age of the ACADIA Pharmaceuticals board of directors in years:

3.5
Average Tenure
61
Average Age
  • The tenure for the ACADIA Pharmaceuticals board of directors is about average.
Board of Directors

Stephen Biggar

TITLE
Chairman of the Board
COMPENSATION
$352K
AGE
47
TENURE
2.8 yrs

Steve Davis

TITLE
CEO & Director
COMPENSATION
$15M
AGE
57
TENURE
3.6 yrs

Laura Brege

TITLE
Independent Director
COMPENSATION
$330K
AGE
60
TENURE
10.9 yrs

Dan Soland

TITLE
Independent Director
COMPENSATION
$575K
AGE
62
TENURE
4.1 yrs

Carol Tamminga

TITLE
Member of the Scientific and Clinical Advisory Board

Herb Meltzer

TITLE
Member of the Scientific and Clinical Advisory Board

Arvid Carlsson

TITLE
Member of the Scientific and Clinical Advisory Board
AGE
95

Paul Anderson

TITLE
Member of the Scientific and Clinical Advisory Board
AGE
79

Ed Harrigan

TITLE
Director
COMPENSATION
$556K
AGE
65
TENURE
3.4 yrs

Jim Baker

TITLE
Independent Director
COMPENSATION
$307K
AGE
51
TENURE
3.3 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
04. Dec 18 Buy Baker Bros. Advisors LP Company 30. Nov 18 30. Nov 18 11,764,705 €15.01 €176,639,987
24. Sep 18 Buy Baker Bros. Advisors LP Company 20. Sep 18 20. Sep 18 1,210,776 €16.25 €19,274,852
X
Management checks
We assess ACADIA Pharmaceuticals's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. ACADIA Pharmaceuticals has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis. It is also developing pimavanserin as a treatment for dementia-related psychosis and as an adjunctive treatment for schizophrenia that are in Phase III clinical trials; and pimavanserin as an adjunctive treatment for major depressive disorder. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.

Details
Name: ACADIA Pharmaceuticals Inc.
DR6
Exchange: DB
Founded: 1993
$3,105,429,544
143,882,381
Website: http://www.acadia-pharm.com
Address: ACADIA Pharmaceuticals Inc.
3611 Valley Centre Drive,
Suite 300,
San Diego,
California, 92130,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGS ACAD Common Stock Nasdaq Global Select US USD 27. May 2004
DB DR6 Common Stock Deutsche Boerse AG DE EUR 27. May 2004
Number of employees
Current staff
Staff numbers
430
ACADIA Pharmaceuticals employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/25 20:34
End of day share price update: 2019/04/25 00:00
Last estimates confirmation: 2019/04/24
Last earnings filing: 2019/02/27
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.